Adcock Ingram Breaks Into Biosimilars With Infliximab

As Pandemic Disrupts Annual Prescription Sales

 
• By Dean Rudge
running athletic race track with blending South Africa flag
Adcock Ingram has debuted its first biosimilar product • Source: Shutterstock

More from Biosimilars

More from Products